Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus.

Arnaud DevresseMarianne Leruez-VilleAnne ScemlaVéronique Avettand-FenoelLise MorinXavier LebretonClaire TinelLucile AmroucheLionel LamhautMarc Olivier TimsitJulien ZuberChristophe LegendreDany Anglicheau

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2018)

Our data suggest that de novo use of EVL may reduce late onset CMV primary disease after the withdrawal of antiviral prophylaxis in kidney transplantation patients.

Keyphrases

late onset
early onset
kidney transplantation
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
peritoneal dialysis
prognostic factors
electronic health record
machine learning
big data
artificial intelligence
data analysis